Transgene Cancer Drugs Clinical Pipeline Insight

Reports
Published
Number of pages
32

For Wire/Bank transfer, contact us at info@pnspharma.com

Electronic Access - Single User License
$500
CD-ROM Mail Delivery
$800
Hard Copy Mail Delivery
$800
Electronic Access - Multi-User License
$1000

“Transgene - Cancer Drugs Clinical Pipeline Insight” offers in depth insight on ongoing clinical trials for the cancer drugs developed by Transgene. This report highlights various clinical and non-clinical parameters involved in the development of cancer drugs in clinical pipeline. Currently there are “6” cancer drugs in clinical pipeline and majority of them are in preclinical phase.

The report includes all the relevant information with respect to development of cancer drugs in the clinical pipeline. Report helps the reader in identifying various data and information points like Drug Class, Mechanism of Action, Granted Orphan Designation, Fast Track Development Status, Clinical Introduction, Drug Formulation/ Route, Owner/License, Multiple Development Phase of particular drug and Patent Information.

“Transgene - Cancer Drugs Clinical Pipeline Insight” report is comprehensively researched and well drafted encyclopedia which helps to analyze and understand the various parameters involved in the clinical development of cancer drugs by the respective company. This research publication also helps in identifying the long term investment and partnering opportunity for the various stake holders of the pharmaceutical industry.

1. Transgene

  1.1 Business Overview

  1.2 Transgene Cancer Pipeline Overview

 

2. Transgene Cancer Drugs in Preclinical Phase

  2.1 Oncolytic Viruses - Transgene

  2.2 Monoclonal Antibodies - Transgene

 

3. Transgene Cancer Drugs in Clinical Phase

  3.1 Tipapkinogene Sovacivec

 

4. Transgene Cancer Drugs in Phase-I/II

  4.1 TG 1042

 

5. Transgene Cancer Drugs in Phase-II/III

  5.1 TG 4010

 

6. Transgene Cancer Drugs in Phase-III

  6.1 Pexastimogene Devacirepvec

 

7. No Development Reported in Cancer Drugs in Clinical Pipeline

  7.1 Melanoma Vaccines - NCI/Transgene

  7.2 Cancer Immunotherapy - Antigen Express/Transgene

  7.3 pcTG90 Gene Delivery Systems

 

8. Discontinued in Cancer Drugs in Clinical Pipeline

  8.1 TG 4023

  8.2 Human Papilloma Virus Genetic Vaccine - Transgene

  8.3 Interferon beta Gene Therapy

 

9. Suspended in Cancer Drugs in Clinical Pipeline

  9.1 Interleukin-2 Gene Therapy - Transgene

Figure 1-1: Transgene Cancer Pipeline by Phase (%)

Figure 1-2: Transgene Cancer Pipeline by Phase (Number)

Figure 1-3: Transgene Cancer Drugs Discontinued & Suspended in Clinical Pipeline by Phase (%)

Figure 1-4: Transgene Cancer Drugs Discontinued & Suspended in Clinical Pipeline by Phase (Number)